Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00841204 · ClinicalTrials.gov registry record · Phase 2

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

A Phase 2 study of Precancerous Condition, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
50
Enrollment target
2
Study locations

NCT00841204: Completed Phase 2 study of Precancerous Condition, sponsored by National Cancer Institute (NCI).

NCT00841204 is a Phase 2 study of Precancerous Condition that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 619-participant average among 15 other Precancerous Condition trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00841204, a Phase 2 study of Precancerous Condition, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.

Conditions Studied

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER placebo
  • DRUG sulindac

Study Locations (2)

Arizona

  • University of Arizona Health Sciences Center - Tucson

California

  • Stanford University Hospitals and Clinics - Stanford

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2009-02
Est. Completion 2011-02
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00841204 record still lists

NCT00841204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 619-participant average among 15 other Precancerous Condition trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Precancerous Condition appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00841204 reports a single indexed study location in Arizona, California.

Frequently Asked Questions

What is clinical trial NCT00841204 about?

NCT00841204 is a clinical study titled "Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma". This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more ef...

What is the current status of trial NCT00841204?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-02. Estimated completion is 2011-02.

What conditions does trial NCT00841204 study?

This clinical trial studies the following conditions: Precancerous Condition.

What interventions are being tested in trial NCT00841204?

The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), sulindac (DRUG).

Who is sponsoring clinical trial NCT00841204?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00841204 being conducted?

This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Precancerous Condition

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00841204's enrollment target sits among peer trials

50 14th of 15 higher than 2 of 15 other Precancerous Condition trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Precancerous Condition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00841204, the US trial registry maintained by the National Library of Medicine. NCT00841204 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.